Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
About this item
Full title
Author / Creator
Flaherty, Kevin R , Wells, Athol U , Cottin, Vincent , Devaraj, Anand , Walsh, Simon L.F , Inoue, Yoshikazu , Richeldi, Luca , Kolb, Martin , Tetzlaff, Kay , Stowasser, Susanne , Coeck, Carl , Clerisme-Beaty, Emmanuelle , Rosenstock, Bernd , Quaresma, Manuel , Haeufel, Thomas , Goeldner, Rainer-Georg , Schlenker-Herceg, Rozsa , Brown, Kevin K and INBUILD Trial Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In patients with a progressive interstitial lung disease, 62% of whom had a CT pattern of usual interstitial pneumonia, those who received nintedanib had a lower annual rate of decline in the forced vital capacity than those who received placebo at 52 weeks.
Alternative Titles
Full title
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Authors, Artists and Contributors
Author / Creator
Wells, Athol U
Cottin, Vincent
Devaraj, Anand
Walsh, Simon L.F
Inoue, Yoshikazu
Richeldi, Luca
Kolb, Martin
Tetzlaff, Kay
Stowasser, Susanne
Coeck, Carl
Clerisme-Beaty, Emmanuelle
Rosenstock, Bernd
Quaresma, Manuel
Haeufel, Thomas
Goeldner, Rainer-Georg
Schlenker-Herceg, Rozsa
Brown, Kevin K
INBUILD Trial Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2310710388
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2310710388
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1908681
